EA036704B1 - Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита - Google Patents

Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита Download PDF

Info

Publication number
EA036704B1
EA036704B1 EA201692050A EA201692050A EA036704B1 EA 036704 B1 EA036704 B1 EA 036704B1 EA 201692050 A EA201692050 A EA 201692050A EA 201692050 A EA201692050 A EA 201692050A EA 036704 B1 EA036704 B1 EA 036704B1
Authority
EA
Eurasian Patent Office
Prior art keywords
nash
nafld
mbx
treatment
alcoholic
Prior art date
Application number
EA201692050A
Other languages
English (en)
Russian (ru)
Other versions
EA201692050A1 (ru
Inventor
Брайан Робертс
Сюэянь Ванг
Юнь-Цзюн Чой
Дэвид Карпф
Роберт Мартин
Чарльз А. Макуэртер
Original Assignee
Саймабэй Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA036704(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Саймабэй Терапьютикс, Инк. filed Critical Саймабэй Терапьютикс, Инк.
Publication of EA201692050A1 publication Critical patent/EA201692050A1/ru
Publication of EA036704B1 publication Critical patent/EA036704B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
EA201692050A 2014-04-11 2015-04-10 Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита EA036704B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11
PCT/US2015/025416 WO2015157697A1 (en) 2014-04-11 2015-04-10 Treatment of nafld and nash

Publications (2)

Publication Number Publication Date
EA201692050A1 EA201692050A1 (ru) 2017-01-30
EA036704B1 true EA036704B1 (ru) 2020-12-10

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692050A EA036704B1 (ru) 2014-04-11 2015-04-10 Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита

Country Status (27)

Country Link
US (7) US9381181B2 (enExample)
EP (1) EP3129018B1 (enExample)
JP (1) JP6865038B2 (enExample)
KR (1) KR102374499B1 (enExample)
CN (1) CN106163508A (enExample)
AU (1) AU2015243239B2 (enExample)
BR (1) BR112016023269A8 (enExample)
CA (1) CA2944139C (enExample)
CL (1) CL2016002517A1 (enExample)
CY (1) CY1122602T1 (enExample)
DK (1) DK3129018T3 (enExample)
EA (1) EA036704B1 (enExample)
ES (1) ES2764467T3 (enExample)
HR (1) HRP20192299T1 (enExample)
IL (1) IL248193B (enExample)
LT (1) LT3129018T (enExample)
MX (1) MX369921B (enExample)
NZ (1) NZ724740A (enExample)
PH (1) PH12016501978B1 (enExample)
PL (1) PL3129018T3 (enExample)
PT (1) PT3129018T (enExample)
RS (1) RS59637B1 (enExample)
SG (1) SG11201608077PA (enExample)
SI (1) SI3129018T1 (enExample)
SM (1) SMT202000019T1 (enExample)
UA (1) UA121208C2 (enExample)
WO (1) WO2015157697A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
BRPI0920170A2 (pt) * 2008-10-17 2016-06-21 Metabolex Inc métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
MX350088B (es) 2009-04-29 2017-08-25 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
CA3067012C (en) 2012-06-29 2021-10-05 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
HRP20181914T1 (hr) 2014-03-20 2019-01-11 Cymabay Therapeutics, Inc. Liječenje intrahepatičnih kolestatskih bolesti
SG11201608077PA (en) 2014-04-11 2016-10-28 Cymabay Therapeutics Inc Treatment of nafld and nash
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
AU2016235263A1 (en) * 2015-03-26 2017-10-12 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives
US20180104201A1 (en) 2015-04-28 2018-04-19 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en) * 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
SG11201903697WA (en) * 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
WO2018204775A1 (en) 2017-05-05 2018-11-08 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN111093705A (zh) 2017-09-13 2020-05-01 诺华股份有限公司 包含fxr激动剂的组合
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
CN111511372A (zh) * 2017-10-27 2020-08-07 株式会社三养社 预防或减轻非酒精性脂肪肝疾病的组合物
PT3720431T (pt) 2017-12-06 2024-12-05 Basf As Derivados de ácidos gordos para o tratamento da esteato-hepatite não alcoólica
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
EP3880187A1 (en) * 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
EP3880185A1 (en) * 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
US20210145774A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
CA3183413A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
WO2022043367A1 (en) 2020-08-26 2022-03-03 Genfit Compositions and methods for the treatment of primary biliary cholangitis
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
US20240216312A1 (en) * 2021-05-11 2024-07-04 Genfit Ppar-agonists for use in the treatment of liver failure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033231A2 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica N.V. Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
EP0813539B1 (en) 1995-03-06 2006-05-24 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
KR19990082476A (ko) 1996-02-14 1999-11-25 하우스 한스 루돌프, 긴터 베아트리체 당-변형되어 갭이 형성된 올리고뉴클레오티드
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP2100877B1 (en) 2003-09-19 2012-01-25 Janssen Pharmaceutica N.V. 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs
NZ549721A (en) 2004-03-05 2010-08-27 Univ Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
BRPI0920170A2 (pt) 2008-10-17 2016-06-21 Metabolex Inc métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2015077154A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
HRP20181914T1 (hr) 2014-03-20 2019-01-11 Cymabay Therapeutics, Inc. Liječenje intrahepatičnih kolestatskih bolesti
SG11201608077PA (en) * 2014-04-11 2016-10-28 Cymabay Therapeutics Inc Treatment of nafld and nash
MX2016017081A (es) 2014-06-26 2017-05-01 Cymabay Therapeutics Inc Tratamiento de hipertrigliceridemia grave.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033231A2 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica N.V. Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAYS HAROLD E ET AL: "MBX-8025, A Novel Peroxisome Proliferator Receptor-delta Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 96, no. 9, 13 June 2012 (2012-06-13), US, pages 2889 - 2897, XP002677652, ISSN: 0021-972X *
SAHEBKAR, AMIRHOSSEIN; CHEW, GERARD T.; WATTS, GERALD F.: "New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease", EXPERT OPIN PHARMACOTHER, ASHLEY PUBLICATIONS LTD, LONDON, UK, vol. 15, no. 4, 1 March 2014 (2014-03-01), London, UK, pages 493 - 503, XP009182172, ISSN: 1465-6566, DOI: 10.1517/14656566.2014.876992 *

Also Published As

Publication number Publication date
LT3129018T (lt) 2020-01-10
US20200009092A1 (en) 2020-01-09
DK3129018T3 (da) 2020-01-20
EP3129018A1 (en) 2017-02-15
EA201692050A1 (ru) 2017-01-30
US9381181B2 (en) 2016-07-05
HRP20192299T1 (hr) 2020-03-06
IL248193B (en) 2019-03-31
US9616039B2 (en) 2017-04-11
PH12016501978B1 (en) 2023-07-12
AU2015243239A1 (en) 2016-10-20
BR112016023269A8 (pt) 2021-06-29
US11179359B2 (en) 2021-11-23
AU2015243239B2 (en) 2019-11-14
CA2944139A1 (en) 2015-10-15
EP3129018B1 (en) 2019-10-23
JP2017513836A (ja) 2017-06-01
UA121208C2 (uk) 2020-04-27
PT3129018T (pt) 2020-01-15
MX2016013375A (es) 2017-02-15
ES2764467T3 (es) 2020-06-03
NZ724740A (en) 2019-11-29
PH12016501978A1 (en) 2016-12-19
BR112016023269A2 (pt) 2017-08-15
US20180228752A1 (en) 2018-08-16
RS59637B1 (sr) 2020-01-31
CY1122602T1 (el) 2021-03-12
CL2016002517A1 (es) 2017-05-05
SMT202000019T1 (it) 2020-03-13
WO2015157697A1 (en) 2015-10-15
SG11201608077PA (en) 2016-10-28
US10342770B2 (en) 2019-07-09
US20160324812A1 (en) 2016-11-10
US10722483B2 (en) 2020-07-28
US10188620B2 (en) 2019-01-29
US20210038546A1 (en) 2021-02-11
MX369921B (es) 2019-11-26
US20190142776A1 (en) 2019-05-16
US9962346B2 (en) 2018-05-08
PL3129018T3 (pl) 2020-05-18
JP6865038B2 (ja) 2021-04-28
US20150290154A1 (en) 2015-10-15
CN106163508A (zh) 2016-11-23
KR20160136451A (ko) 2016-11-29
KR102374499B1 (ko) 2022-03-14
CA2944139C (en) 2020-11-03
SI3129018T1 (sl) 2020-02-28
US20180008566A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
US11179359B2 (en) Treatment of NAFLD and NASH
JP6568577B2 (ja) 肝内胆汁うっ滞症の治療
KR20210092754A (ko) Nafld 및 nash의 병용 치료
WO2020102351A1 (en) Treatment of obesity and its complications
KR102408288B1 (ko) 간내 담즙 정체성 질환의 치료
HK1228275A1 (en) Treatment of nafld and nash
HK1228275B (en) Treatment of nafld and nash